ENTRIES TAGGED "data collection"
Big Data and analytics are the foundation of personalized medicine
Despite considerable progress in prevention and treatment, cancer remains the second leading cause of death in the United States. Even with the $50 billion pharmaceutical companies spend on research and development every year, any given cancer drug is ineffective in 75% of the patients receiving it. Typically, oncologists start patients on the cheapest likely chemotherapy (or the one their formulary suggests first) and in the 75% likelihood of non-response, iterate with increasingly expensive drugs until they find one that works, or until the patient dies. This process is inefficient and expensive, and subjects patients to unnecessary side effects, as well as causing them to lose precious time in their fight against a progressive disease. The vision is to enable oncologists to prescribe the right chemical the first time–one that will kill the target cancer cells with the least collateral damage to the patient.
How data can improve cancer treatment
Big data is enabling a new understanding of the molecular biology of cancer. The focus has changed over the last 20 years from the location of the tumor in the body (e.g., breast, colon or blood), to the effect of the individual’s genetics, especially the genetics of that individual’s cancer cells, on her response to treatment and sensitivity to side effects. For example, researchers have to date identified four distinct cell genotypes of breast cancer; identifying the cancer genotype allows the oncologist to prescribe the most effective available drug first.
Herceptin, the first drug developed to target a particular cancer genotype (HER2), rapidly demonstrated both the promise and the limitations of this approach. (Among the limitations, HER2 is only one of four known and many unknown breast cancer genotypes, and treatment selects for populations of resistant cancer cells, so the cancer can return in a more virulent form.)
Increasingly available data spurs organizations to make analysis easier
Genomics is making headlines in both academia and the celebrity world. With intense media coverage of Angelina Jolie’s recent double mastectomy after genetic tests revealed that she was predisposed to breast cancer, genetic testing and genomics have been propelled to the front of many more minds.
In this new data field, companies are approaching the collection, analysis, and turning of data into usable information from a variety of angles.
Kate Crawford argues for caution and care in data-driven decision making.
Microsoft principal researcher Kate Crawford (@katecrawford) gave a strong talk at last week’s Strata Conference in Santa Clara, Calif. about the limits of big data. She pointed out potential biases in data collection, questioned who may be excluded from it, and hammered home the constant need for context in conclusions. Video of her talk is embedded below:
Crawford explored many of these same topics in our interview, which follows.
The evolution of Safecast is a glimpse into networked accountability.
After a tsunami caused a nuclear disaster in Japan, a radiation detection network starting aggregating and publishing data. The result, Safecast, shows how citizen science and open data are changing our understanding of the world.
How to communicate the value of data to people who don't live and breathe it.
Companies that want to move personal data collection into the mainstream must offer utility, serendipity, and self-expression. You either have to be great at one or address all three.